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ABSTRACT
Platelet-derived growth factors are a family of
mitogens and chemoattractants comprising of
four ligand genes (A-, B-, C-, D-chains) implicated
in many physiologic and pathophysiologic proce-
sses, including atherosclerosis, fibrosis and tumor-
igenesis. Our understanding of the molecular
mechanisms, which regulate PDGF-C transcription
remains incomplete. Transient transfection analysis,
conventional and quantitative real-time PCR
revealed the induction of PDGF-C transcription and
mRNA expression in smooth muscle cells (SMCs)
exposed to the peptide hormone angiotensin (ATII),
which induces Egr-1. Occupancy of a G+C-rich
element in the proximal region of the PDGF-C
promoter was unaffected by ATII. Instead we
discovered, using both nuclear extracts and recom-
binant proteins with EMSA and ChIP analyses, the
existence of a second Egr-1-binding element
located 500bp upstream. ATII induction of PDGF-C
transcription is mediated by the angiotensin type 1
receptor (AT1R) and Egr-1 activation through this
upstream element. DNAzyme ED5 targeting Egr-1
blocked ATII-inducible PDGF-C expression. More-
over, increased PDGF-C expression after exposure
to ATII depends upon the differentiation state of the
SMCs. This study demonstrates the existence of
this novel ATII-AT1R-Egr-1-PDGF-C axis in SMCs of
neonatal origin, but not in adult SMCs, where ATII
induces Egr-1 but not PDGF-C.
INTRODUCTION
Platelet-derived growth factor-C (PDGF-C) (1), like
PDGF-D are the two most recently identiﬁed members
of the PDGF family of growth factors, which includes the
well-characterized PDGF-A and PDGF-B. PDGFs are
important regulators of cell proliferation and survival
in many types of mesenchymal cells including smooth
muscle cells (SMCs), connective tissue cells and ﬁbro-
blasts. Studies over the last two decades have implicated
PDGF-A and -B in pathophysiologic processes such as
atherosclerosis, restenosis, ﬁbrosis and tumorigenesis
(2,3). Since its discovery in the same year as PDGF-D,
PDGF-C has been found to participate in ﬁbrotic disease
(4,5), angiogenesis (6,7), embryogenesis (8–10), palate
formation (11) and platelet activation (12). The human
PDGFC gene is located on chromosome 4q32, which
encodes a 345 amino acid protein with a two-domain
structure: an N-terminal CUB-domain and a C-terminal
growth factor domain (GFD). PDGF-CC is produced as a
latent factor, requiring thereby activation by proteolysis to
release the GFD from the CUB domain (1). PDGF-C
mRNA is expressed in most human adult tissues, with
highest levels in heart, kidney and pancreas and smaller
amount are found in placenta, skeletal muscle and
prostate (1,5,7).
Angiotensin II (ATII), the eﬀector peptide of the renin-
angiotensin system, is involved in blood pressure control,
vascular tone and growth factor induction. Additionally,
ATII is a pro-atherogenic factor as it is capable of
stimulating vascular SMC proliferation through the
generation of complex signaling events (13) that aﬀect
the expression of pathophysiologically relevant genes such
as PDGF-A (14), PDGF-B (15) and PDGF-D (16).
Vascular SMCs respond to ATII multiphasic manner:
within seconds, ATII can activate PLC and Ca
2+
mobilization; within minutes, protein kinase C (PKC)
and phospholipase D (PLD) are activated; and within
hours, NADH/NADPH oxidase activity is stimulated
(17). The SMC response to ATII is inﬂuenced by its
diﬀerentiation state (17). For example, in both cultured
newborn rat arterial medial SMCs and rat arterial
neointimal SMCs, PDGF-B mRNA expression is induced
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observed in rat adult SMCs (15). SMC heterogeneity is a
well-known feature of this cell type (18). The ‘contractile’
state, which is typical of the diﬀerentiated artery (19,20),
whereas the ‘synthetic’ state is characteristic of
developing or pathologic arteries and the SMCs exhibit
an epithelioid shape with enhanced proliferative and
migratory activity.
ATII has previously been shown to regulate PDGF-A
(14), PDGF-B (15) and PDGF-D (16) transcription,
however the ATII-inducible expression of each isoform
may be mediated by distinct mechanisms. In the case of
PDGF-D, ATII acts through reactive oxygen species
(ROS), speciﬁcally H2O2 and Ets-1, whereas ATII-
inducible PDGF-B expression, although not yet fully
elucidated, has been shown to be dependent on Ras, ERK
and c-Jun-terminal kinase (JNK) signaling. Furthermore,
ATII activates the extracellular signal-related kinase
(ERK) pathway to stimulate Egr-1 and PDGF-A expres-
sion via a G+C-rich region (located  76 to  47bp) in
the proximal PDGF-A promoter bearing Egr-1-binding
elements (14,21). This element is strikingly similar to
that in the proximal PDGF-C promoter (22). Egr-1
mediates inducible PDGF-A and PDGF-C transcription
in cells exposed to FGF-2 through this proximal element
(22,23). Since this element controls inducible PDGF-A
expression in cells exposed to a variety of other agonists
and conditions [such as ATII (14), PMA (21) and shear
stress (24)], we hypothesized that this element in the
PDGF-C promoter regulates altered expression in
response to other stimulants. It is presently unknown
whether ATII regulates the PDGF-C gene. This demon-
stration is important, as it would place ATII as an
agonist governing the expression of every known PDGF
ligand.
This study reveals the existence of a second functional
Egr-1-binding element in the PDGF-C promoter located
 500bp upstream of the proximal G+C-rich element
previously shown by us to mediate FGF-2-inducible
PDGF-C transcription (22). We report that ATII
induction of PDGF-C transcription is mediated by the
angiotensin type 1 receptor (AT1) and Egr-1 activation
through this upstream element. Moreover, we demon-
strate that ATII-inducible PDGF-C expression is
SMC diﬀerentiation state-dependent and that the two
Egr-1-binding elements operate independently.
MATERIALS AND METHODS
Chemicals
ATII (Sigma) was dissolved in water (Baxter), aliquoted
and stored at –808C. The ATII receptor inhibitor
PD123319 was purchased from Sigma and Losartan was
a generous gift from Merck, Sharp & Dohme (Sydney,
Australia).
Cellculture
WKY12-22 rat neonatal (pup) aortic SMCs and adult
rat aortic SMCs were cultured in Waymouth’s MB752/1
medium (Life Technologies, Inc.), pH 7.4, supplemented
with 10 U/ml penicillin, 10mg/ml streptomycin and 10%
fetal calf serum at 378C and 5% CO2 in an Air Jacket
CO2 incubator (model 60A0100a, Thermoline). At 90%
conﬂuence, the cells were rinsed twice with phosphate-
buﬀered saline (PBS) solution and passaged by incubating
with 0.05% trypsin and 0.02% ethylenediaminetetraacetic
acid (EDTA) in Hank’s balanced salt solution
(BioWhittaker) for 1–3min at 378C and then tapping
ﬁrmly. The cells were resuspended in growth medium
and placed in 75cm
2 ﬂasks. The SMCs were growth-
arrested in serum-free media for 24h prior to stimulation
with ATII (10
 7M). In ATII receptor inhibitor studies,
WKY12-22 cells were incubated with Losartan (1mM)
or PD123319 (1mM) for 1h and then treated with ATII
for 2h before mRNA extraction.
Total RNA preparationand reverse transcriptase reaction
Cells were washed twice with cold PBS and total RNA
was extracted with TRIzol (Life Technologies, Inc.).
cDNA was synthesized from 5mg of RNA using the Super
Script III First Strand Synthesis Kit (Invitrogen,
Carlsbad, USA) as per manufacturer’s instructions.
cDNA was stored at  208C.
Semi quantitative polymerasechain reaction (PCR)
PCR was performed utilizing the Platinum Tag polymer-
ase kit. cDNA was ampliﬁed for PDGF-C, Egr-1
products. The set of primers used for rat PDGF-C was:
forward, 50 -GGC ATG AGA GAG TTG TCA CTA
TAT CTG GTA-30, and reverse, 50 -GTC CAA GTC TAT
CTG CCA TCG ATC T-30 with denaturing temperature
of 988C for 1min, followed by 22 cycles of 968C for 30s,
608C for 30s, 728C for 30s and extending at 728C for
5min, producing a 481bp fragment. For rat Egr-1
ampliﬁcation, primers used were: forward, 50-GCC TTT
TGC CTG TGA CAT TT-30, and reverse, 50-AGC CCG
GAG AGG AGT AAG AG-30, with ampliﬁcation
conditions of 988C for 1min; 948C for 30s, 608C for
30s, 728C for 30s repeated 30 times; 728C for 1min,
producing a 230bp amplicon. Rat beta-actin was used as
a housekeeping gene. Primers used were, forward, 50-AGC
CAT GTA CGT AGC CAT CC-30, and reverse, 50-CTC
TCA GCT GTG GTG GTG AA-30. The cycling condi-
tions were 988C for 1min, followed by 20 cycles at 948C
for 30s, 588C for 30s, 728C for 30s, ﬁnishing with 728C
for 2min, amplifying a 228bp product. PCR products
were electrophoresed on 1.5% (w/v) agarose gel in
1 TBA-EDTA at 90V for 55min in TBE buﬀer.
Products were visualized by transillumination using the
Gel Doc 2000 photographic system and Quantity One
version 4.1.1 software.
Quantitative real-time PCR
Real-time quantitative PCR was performed using ABI
PRISM7700 Sequence Detection System in a ﬁnal volume
of 25ml containing 1ml of cDNA, 12.5ml of SYBR
Green Master Mix (Applied Biosystems), 0.5mMo f
forward and reverse primers (Sigma) in DNAse-free
water at the following PCR conditions: 508C for 2min,
followed by 40 cycles of 958C for 15s and 608C for 1min.
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AGA TGG TGA AGG TCG GTG -30; (reverse) 50-AGA
AGG CAG CCC TGG TAA CC-30; and for rat PDGF-C
(forward) 50-CAG CAA GT GCA GCT CTC CA-30;
(reverse) 50-GAC AAC TCT CTC ATG CCG GG -30.
Primer product size was veriﬁed on a 2% agarose/TBE
gel. As an internal control and for normalization
purposes, the level of mRNA expression for GAPDH, a
housekeeping gene, was measured simultaneous to
PDGF-C expression for each sample. The results are
presented as relative amounts of PDGF-C mRNA
versus the housekeeping mRNA value for the same
sample. Statistical analysis was performed by paired
t-test (
 denotes P<0.05) and compared with untreated
controls.
Western blot analysis
WKY 12-22 SMCs were grown in 100mm petri dishes,
rendered growth quiescent by incubating in serum-free
medium for 24h and agonist was added for the times
indicated or transfection was performed (pCB6-Egr-1
and CMV-Sp1). SMCs were washed twice with cold
PBS and lyzed with RIPA buﬀer containing protease
inhibitors (150mM NaCl, 50mM Tris–HCl pH 7.5, 1%
deoxycholate, 0.1% Triton X-100, 5mg/ml leupeptin,
100mM PMSF, 10% Trasylol, 0.5M EDTA).
The suspension was centrifuged for 10min and the
supernatant was collected. Protein estimation was carried
out by BCA protein assay kit (Pierce, Rockford, IL,
USA). Six microliters of 4 SDS protein loading
sample buﬀer along with 2ml of 0.5M DTT and 20 or
10mg of lysates (dependent upon the experiment)
were boiled for 5min. Proteins were resolved in 10%
SDS–PAGE and transferred onto Immobilon-P transfer
membranes (Millipore). Membranes were blocked
overnight with 5% skimmed milk in 1% PBS, 0.05%
Tween-20at 48C. Membranes were then incubated with
antibodies to Egr-1 (1:1000), Sp1 (1:1000) and beta-actin
(1:30000) for 1h at 228C followed by incubation with
their respective secondary antibody [anti-rabbit, anti-goat
and anti-mouse IgG conjugated with horseradish
peroxidase (HRP)] for 1h. Membranes were incubated
with chemiluminescence (Perkin Elmer Life Sciences,
Shelton, CT) for 1min and then exposed the ﬁlm for
1–5min.
PDGF plasmid constructs
The ‘Fireﬂy’ luciferase-based reporter construct pPDGF-
C-797 was described previously (22). A mutant form of
this construct (pPDGF-C-797.mutEgr-1) was prepared
using Quick Change site-directed mutagenesis kit
(Stratagene) with the following primers (forward:
50- CGG GAG AGC CGC TGA GCA TAA AAA TAT
CGC CAG GCG CGC GCT C-30 and reverse: 50-GAG
CGC GCG CCT GGC GAT ATT TTT ATG CTC AGC
GGC TCT CCC G-30) targeting the  560 to  518bp
region of the PDGF-C promoter (relative to ATG site).
The integrity of the reporter construct was conﬁrmed by
nucleotide sequencing. CMV-Sp1 and pCB6-Egr-1 were
generous gifts of Robert Tjian and Vikas Sukhatme,
respectively.
Transient transfections
SMCs were seeded in 100mm dishes and grown to 60%
conﬂuence and serum-arrested for 24h before transfection
with FuGENE6 (Roche Applied Science) at a ratio of
3ml of FuGENE6 per microgram of DNA, with 5mgo f
reporter construct pPDGF-C-797 and 0.5mg of pRL-null,
an internal control vector. In overexpression studies,
SMCs were co-transfected with 1, 2 or 3mg of either pCB6,
pCB6-Egr-1, CMV-gutless, CMV-Sp1 or both pCB6
and CMV-gutless or pCB6-Egr-1 and CMV-Sp1. After
incubation at 378C for 24h, luciferase activity was
quantiﬁed using the Dual-Luciferase Reporter Assay
(Promega). ‘Fireﬂy’ luciferase activity was normalized
to ‘Renilla’ data generated from pRL-null. When the
eﬀect of ED5 (0.4mM), or its scrambled counterpart,
ED5SCR was assessed, a ‘double hit’ transfection was
used to maximize DNAzyme suppression of Egr-1
expression (ﬁrst transfection 18h prior to agonist stimula-
tion of Egr-1, and the second, at the time of the stimulus).
This pre-emptive delivery approach enables cellular
uptake of the DNAzyme before Egr-1 is acutely induced
by ATII. This routinely results in >75% uptake in our
laboratory as determined by ﬂuorescence microscopy with
transfected FITC-labeled DNAzyme (25).
Preparation ofnuclear extracts andelectrophoretic
mobility shift assay(EMSA)
Nuclear extracts were prepared and EMSA was performed
as previously described (22).
Statistical methods
Data was analyzed for statistical signiﬁcance using
Student’s t-test, and considered signiﬁcant when
P<0.05. Error bars represent the mean SE.
Chromatin immunoprecipitation analysis (ChIP)
ChIP assays were performed with human SMCs at 80%
conﬂuency using a modiﬁcation of a protocol previously
described (26). Brieﬂy, cross-linking was performed
by the addition of 37% (w/v) formaldehyde for 15min,
followed by glycine incorporation to a ﬁnal concentration
125mM. The cells were washed with PBS, followed by
1ml of immunoprecipitation (IP) buﬀer with protease
inhibitors (26). Lysates were sonicated on ice for six
rounds of 15 1s pulses (output level 7) and then
centrifuged at 14000 r.p.m. for 10min. Supernatants
were fractioned evenly into tubes and incubated with anti-
Sp1 and anti-Egr-1 antibodies (Santa Cruz Biotechnology,
Inc.) for 30min at 228C, then at 48C for 15min, followed
by centrifugation for 10min at full speed. Prewashed
Protein-A and -G beads were added and the slurry was
rotated for 45min at 48C. The beads were washed ﬁve
times with IP buﬀer without inhibitors prior the addition
of 100ml of 10% Chelex-100 and boiled for 10min.
Samples were digested with proteinase K (100mg/ml) for
30min at 558C, then boiled for 10min centrifuged and
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chloroform extraction and ethanol precipitation. DNA
was dissolved in water and used for PCR reaction in 1mM
MgCl2, 0.1mM dNTPs, 0.1mM of primers and 1 U
Platinum Taq Polymerase (Invitrogen). Cycling condi-
tions were: 988C for 1min, 40 cycles of 988C for 30s, 588C
for 30s and 728C for 30s followed by 728C for 2min.
PDGF-C promoter containing the putative Egr-1-binding
site was ampliﬁed (330bp) with the following primers:
forward 50-TAG AGG TGT TCC GTG GAA GG-30 and
reverse 50-TTG TCC CCT CCC CTT CTC TA-30.
RESULTS AND DISCUSSION
ATII has previously been shown to induce PDGF-A (14),
PDGF-B (15) and PDGF-D (16) transcription in
SMCs. To begin to investigate whether ATII can inﬂuence
the expression of PDGF-C, we isolated mRNA from
rat neonatal aortic SMCs (WKY12-22 cells) exposed to
ATII (10
 7M) for various times. Conventional RT-PCR
revealed that PDGF-C was basally expressed and was
transiently induced by ATII, maximally at 2h
(Figure 1A). Quantitative real-time PCR demonstrated a
2-fold increase in PDGF-C mRNA levels at 1h and
maximal 3-fold induction by 2h (Figure 1B). To establish
that PDGF-C is under the transcriptional control of ATII,
transient transfection was performed in WKY12-22 SMCs
with pPDGF-C-797, a ‘Fireﬂy’ luciferase-based reporter
construct bearing 797bp of the PDGF-C promoter, prior
to exposure to ATII (10
 7M). Treatment with ATII
induced PDGF-C promoter activity (Figure 1C).
ATII induction of PDGF-A expression is mediated via
ERK-dependent Egr-1 binding to a G+C-rich region of
the PDGF-A promoter at overlapping Egr-1/Sp1-binding
sites ( 76 to  47bp) (14). To determine whether ATII
induces Egr-1 binding to a similar region in the proximal
PDGF-C promoter, we performed EMSA using nuclear
extracts from WKY12-22 SMCs treated with or without
ATII (10
 7M) for 1h and a
32P-labeled double-stranded
oligonucleotide probe [
32P-Oligo C
( 35/ 1)] previously
shown to bind FGF-2-inducible Egr-1 (22). Four nucleo-
protein complexes formed, three major (Na, Nc, Nd) and
one minor (Nb) (Figure 2A). Supershift analysis using
antibodies targeting Sp1 revealed protein complex Na
contains Sp1 (Figure 2A). However, to our surprise,
antibodies to Egr-1 (or ATF4) did not alter the binding
proﬁle, despite the induction of Egr-1 mRNA and protein
expression by ATII (Figure 2B and C). As a control for
the antibody, we performed EMSA using nuclear extracts
from WKY12-22 SMCs treated with FGF-2 (25ng/ml)
together with
32P-Oligo C
( 35/ 1). As previously obtained
using extracts from FGF-2-treated rat SMCs (22), six
nucleoprotein complexes (N1–N6) formed using
32P-Oligo
C
( 35/ 1), including one complex containing supershiftable
Egr-1 protein (N3) (Figure 2D). These results indicate that
although ATII induces Egr-1 in WKY12-22 SMCs, Egr-1
does not interact with the proximal G+C-rich region of
the PDGF-C promoter.
After further examination of the PDGF-C promoter, we
identiﬁed a second Egr-1-binding element (50-CGCCCC
CGC-30) upstream (at position  543/ 535) (Figure 3).
This putative binding motif resides within the PDGF-C
luciferase-based reporter construct used in Figure 1C,
which was activated by ATII. To establish whether ATII
induces binding to this putative element, we performed
EMSA using nuclear extracts from WKY12-22 SMCs
treated with or without ATII (10
 7M) for 1h, and a
32P-
labeled oligonucleotide probe [
32P-PDGF-C
( 560/ 518)]
whose sequence spans  543/ 535 (Figure 4A). Two
complexes, one more intense (Ni) than the other (Nii),
formed when extracts from untreated SMCs were incu-
bated with
32P-PDGF-C
( 560/ 518) (Figure 4A, lane 2 and
Figure 4B). Complex Nii was induced upon ATII
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Figure 1. ATII induces PDGF-C expression and promoter activation in
neonatal SMCs. Total RNA was isolated from neonatal (WKY12-22)
SMCs cells treated with or without ATII (10
 7M) for various times.
(A) Conventional RT-PCR or (B) real-time PCR was performed for
PDGF-C as described in the Materials and Methods section. The graph
represents PDGF-C expression relative to the expression of GAPDH to
correct for cDNA concentration between samples. (C) Transient
transfection analysis was performed in WKY12-22 SMCs transfected
with 5mg of pPDGF-C-797 and treated with or without ATII (10
 7M)
for 24h. The data are representative of three or more independent
determinations. Error bars represent the mean SE. Asterisk (
 )
denotes P<0.05 compared to control.
1944 Nucleic Acids Research, 2008, Vol. 36, No. 6treatment (Figure 4A, lane 3 and Figure 4B), and
antibody-based complex elimination analysis revealed
it to contain Egr-1 protein (Figure 4A, lane 5 and
Figure 4B). Complex Ni, whose intensity was also
increased by ATII, contains both Sp1 and Egr-1, with
Sp1 the predominant occupant. Sp1 antibodies super-
shifted the complex, whereas Egr-1 antibodies reduced its
intensity (Figure 4A, lanes 4 and 5 and Figure 4B).
In support of these data, Sp1 and Egr-1 are known to
physically interact (27). In contrast, antibodies to ATF4
had no signiﬁcant eﬀect on the binding proﬁle of either
complex (Figure 4A, lane 6 and Figure 4B). These results
indicate that Sp1 interacts basally, and Egr-1 inducibly,
with site  560/ 518 in the PDGF-C promoter. Moreover,
consistent with EMSA, ChIP analysis revealed that under
basal conditions Sp1 is bound to the authentic PDGF-C
promoter (Figure 4C), and that both Egr-1 and Sp1 are
bound to the promoter upon exposure to ATII
(Figure 4C). The identity of the amplicon as a fragment
of the PDGF-C promoter was conﬁrmed by nucleotide
sequencing (data not shown).
In order to conﬁrm the interaction of Sp1 and Egr-1
with this region of the PDGF-C promoter ( 560/ 518bp)
and to determine whether Sp1 and Egr-1 interact
competitively or cooperatively for binding to the over-
lapping site, EMSA was performed using human recom-
binant Sp1 and Egr-1 and
32P-PDGF-C
( 560/ 518)
(Figure 5A). In binding reactions containing either
recombinant Sp1 or Egr-1, a nucleoprotein complex was
not observed. However, a single complex was detected
when both Sp1 and Egr-1 were incubated with the
oligonucleotide
32P-PDGF-C
( 560/ 518) (Figure 5A). This
data suggests that, individually, Sp1 and Egr-1 are unable
to bind this novel element and that presence of the two
transcription factors is required for the formation of a
single nucleoprotein complex. Interestingly, only one
ATII
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Figure 2. ATII does not induce binding to the Egr-1/Sp1-binding site ( 35/ 1bp) in the PDGF-C promoter. (A) EMSA was performed using
nuclear extracts from WKY12-22 SMCs treated with or without ATII (10
 7M) for 1h and
32P-Oligo C
( 35/ 1). Supershift analysis using antibodies
targeting Sp1 demonstrate that nucleoprotein complex Na contains Sp1. Antibodies directed towards Egr-1 reveal that none of the complexes contain
Egr-1 protein. (B) RT-PCR demonstrates that Egr-1 is inducibly expressed in WKY12-22 SMCs exposed to ATII (10
 7M) for the indicated times.
(C) Western blot analysis demonstrates that ATII increases Egr-1 protein expression in WKY12-22 SMCs. (D) EMSA using
32P-Oligo C
( 35/ 1) and
nuclear extracts from WKY12-22 SMCs treated with FGF-2 (25mg/ml) for 1h. Nucleoprotein complexes N1 and N2 contain Sp1, and N3 contains
Egr-1 as demonstrated by antibody-based band elimination.
Nucleic Acids Research, 2008, Vol. 36, No. 6 1945major complex formed when
32P-PDGF-C
( 560/ 518) was
incubated with recombinant Egr-1 and Sp1 (Figure 5A,
arrow), which compares with complex Ni (but not Nii)
containing both nuclear Sp1 and Egr-1 (Figure 4A and B).
To test the hypothesis that Egr-1 and Sp1 co-operatively
transactivate the PDGF-C promoter, we performed
transient transfection analysis with Egr-1 and Sp1 expres-
sion vectors. Transfection with low amounts of Egr-1
results in modest activation of the PDGF-C promoter
(Figure 5B, compare columns 2 and 3 to 1), but in
the presence of Sp1, the same amounts of Egr-1 produced
co-operative activation (Figure 5B, compare columns 5
and 6 to 4).
To determine the nucleotides critical for Egr-1/Sp1
binding to this region of the PDGF-C promoter,
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Figure 4. ATII induces Egr-1 binding to the PDGF-C promoter.
(A) EMSA was performed using nuclear extracts from neonatal SMCs
treated with or without ATII (10
 7M) for 1h and
32P-PDGF-C
( 560/
 518) or
32P-mEgr-1-PDGF-C
( 560/ 518). Two nucleoprotein complexes
(Ni and Nii) formed after incubation of
32P-PDGF-C
( 560/ 518) with
nuclear extracts from cells untreated or treated with ATII. Supershift/
band elimination analysis using antibodies to Sp1 and Egr-1 reveal
complex Ni contains Sp1 and Egr-1, and complex Nii to contain only
Egr-1. Antibodies to ATF4 did not promote shift in any complex. In
reactions containing nuclear extracts from untreated or ATII-treated
SMCs and
32P-mEgr-1-PDGF-C
( 560/ 518) (mutant form of the
oligonucleotide in which consensus Egr-1 site mutated), neither
complex formed. (B) Assessment of band intensities in the
32P-PDGF-C/ATII groups by scanning densitometry. Complex densi-
ties for Ni and Nii are indicated. NT denotes non-ATII-treated.
(C) ChIP studies show that under basal conditions Sp1 is bound to the
authentic PDGF-C promoter, and that both Egr-1 and Sp1 are bound
to the promoter upon exposure to ATII. Asterisk (
 ) denotes P<0.01
relative to ATII.
acccatcgtg ctctgtattt ggggttagag gtgttccgtg
gaagggaaag caggggccgc cttggccgcg ttcctctcct
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Figure 3. Proximal region of the PDGF-C promoter. A consensus Egr-
1-binding element was found  543 to  535bp in the PDGF-C
promoter upstream from the G+C-rich element (located  35 to
 1bp) previously found to contain an overlapping Egr-1/Sp1 site (22).
The Egr-1 consensus element is denoted by bold type and underline
(contained with EMSA probe, PDGF-C
( 560/ 518) denoted by italics),
and the G+C-rich element is deﬁned by bold type and underline.
The relative base pairs are represented by numbers in bold type and the
curved arrow represents the putative transcriptional start site
(as deﬁned by UCSC Genome Database).
1946 Nucleic Acids Research, 2008, Vol. 36, No. 6a transverse mutation was introduced into
32P-PDGF-
C
( 560/ 518), changing the putative Egr-1 element located
 543/ 535bp from 50-CGCCCCCGC-30 to 50-ATAAAA
ATA-30. EMSA was performed using this mutant form of
the oligonucleotide [
32P-mEgr1-PDGF-C
( 560/ 518)] with
nuclear extracts from WKY12-22 SMCs treated with or
without ATII (10
 7M) for 1h (Figure 4). Neither Ni nor
Nii formed under basal or ATII-stimulated conditions,
demonstrating that the integrity of  543/ 535bp is
critical for the interaction of Egr-1 and Sp1 with this
region of the PDGF-C promoter.
To establish the functional signiﬁcance of this novel
element in the PDGF-C promoter, the same transverse
mutation was introduced into pPDGF-C-797 (pPDGF-C-
797.mutEgr-1) and transient transfection was performed
with both wild type and mutant PDGF-C promoter
reporter construct. Transfectants were stimulated with or
without ATII (10
 7M) for 24h and PDGF-C promoter
activation was analyzed using a luminometer. ATII
activated the wild-type PDGF-C promoter by over
7-fold (Figure 6, consistent with Figure 1C), however,
no signiﬁcant diﬀerence was observed in PDGF-C
promoter activity in cells transfected with pPDGF-C-
797.mutEgr-1 treated with ATII or left untreated
(Figure 6).
The preceding data demonstrate that Egr-1 inducibly
binds to a novel upstream element in the PDGF-C pro-
moter. To directly establish that Egr-1 mediates ATII-
inducible PDGF-C expression, we assessed PDGF-C
mRNA levels in neonatal SMCs that had been transfected
with the Egr-1 DNAzyme, ED5 (25) or its arm-scrambled
counterpart, ED5SCR, and stimulated with ATII for 2h.
DNAzymes are sequence-speciﬁc ‘gene knockdown’
agents that bind to and cleave the mRNA of their target
gene (28,29). We have previously used DNAzymes to
inhibit gene expression in SMCs in vitro and neointima
formation in rat carotid arteries after balloon injury (25)
and in pig coronary arteries following stenting (30). Using
both conventional RT-PCR (Figure 7A) and real-time
PCR (Figure 7B), our ﬁndings demonstrate that ED5, but
not ED5SCR, perturbed the stimulatory eﬀect of ATII on
PDGF-C mRNA expression. To support these observa-
tions, we evaluated the eﬀect of ED5 on levels of Egr-1
either by conventional or quantitative real-time PCR.
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Figure 5. Egr-1 and Sp1 cooperatively bind and transactivate the PDGF-C promoter. (A) EMSA was performed using
32P-PDGF-C
( 560/ 518) and
human recombinant Egr-1 (100ng), human recombinant Sp1 (100ng) or both human recombinant Egr-1 and Sp1 (100ng each). A major nucleoprotein
complex formed (arrow) only when recombinant Egr-1 and recombinant Sp1 were both incubated with
32P-PDGF-C
( 560/ 518). The data are
representative of three or more independent determinations. (B) WKY12-22 SMCs were transfected with 0, 1 and 2mg of pCB6-Egr-1 (made up to 4mg
total with its backbone pCB6
+), or identical amounts of pCB6-Egr-1 with 2mg CMV-Sp1 (made up to 4mg total with its backbone pCB6
+), all with
pPDGF-C-797 (5mg) and pRL-null (0.5mg, to normalize for transfection eﬃciency). ‘Fireﬂy’ luciferase activity was normalized to ‘Renilla’. The data are
representative of three or more independent determinations. Error bars represent the mean SE. Asterisk (
 ) denotes P<0.001.
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Figure 6. Novel Egr-1 element in the PDGF-C promoter mediates
ATII-inducible PDGF-C expression. Transient transfection analysis
was performed on WKY12-22 SMCs transfected with pPDGF-C-797
(5mg), or pPDGF-C-797.mutEgr-1 (5mg) and pRL-null (0.5mg, to
normalize for transfection eﬃciency) and treated with or without ATII
(10
 7M) for 24h. ‘Fireﬂy’ luciferase activity was normalized to
‘Renilla’. The data are representative of three or more independent
determinations. Error bars represent the mean SE. Asterisk (
 )
denotes P<0.05.
Nucleic Acids Research, 2008, Vol. 36, No. 6 1947ED5 inhibited the induction of Egr-1 by ATII, whereas
ED5SCR had no eﬀect (Figure 7C and D). These ﬁndings
together demonstrate the dependence of ATII induction of
PDGF-C expression on Egr-1. To demonstrate whether
exogenous Egr-1 enhances the induction of PDGF-C by
ATII, we co-transfected pCB6-Egr-1 or pCB6
+ with
pPDGF-C-797 and luciferase activity was assessed with or
without exposure of the cells to ATII. We observed that a
ﬁxed amount of Egr-1 potentiated ATII-inducible PDGF-
C transcription in an ATII dose-dependent manner
(Figure 7E). Taken together, these data demonstrate
that Egr-1 is critical for ATII-inducible PDGF-C
expression.
We next investigated the ATII receptor subtype
mediating ATII-inducible PDGF-C expression using
pharmacologic inhibitors. mRNA was isolated from
WKY12-22 SMCs treated with Losartan (14), a compet-
itive inhibitor of AT1R, or the AT2R antagonist
PD123319 (14) for 1h (both at 1mM) prior to stimulation
with ATII for 2h. mRNA was reverse-transcribed to
cDNA and real-time PCR was performed for PDGF-C.
Losartan blocked ATII-inducible PDGF-C expression
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Figure 7. DNAzymes targeting Egr-1 block ATII-inducible PDGF-C expression. WKY12-22 SMCs were transfected twice with or without the
DNAzyme ED5 (0.4mM) or its scrambled counterpart ED5SCR (0.4mM) and stimulated with ATII (10
 7M) for 2h. (A) Conventional RT-PCR and
(B) real-time PCR demonstrates the reliance on Egr-1 for ATII-inducible PDGF-C expression. The real-time data represents PDGF-C expression
relative to the expression of GAPDH. (C) Conventional RT-PCR and (D) real-time PCR shows that ED5 (0.4mM) inhibits ATII-inducible Egr-1
expression. The real-time data represents Egr-1 expression relative to the expression of GAPDH. (E) Growth-quiescent WKY12-22 SMCs were
transfected with 2mg pCB6
+ or pCB6-Egr-1, together with pPDGF-C-797 (5mg) and pRL-null (0.5mg, to normalize for transfection eﬃciency), then
exposed to ATII (10
 7 or 10
–6M) for 24h. ‘Fireﬂy’ luciferase activity was normalized to ‘Renilla’. The data are representative of three or more
independent determinations. Error bars represent the mean SE. Asterisk (
 ) denotes P<0.05.
1948 Nucleic Acids Research, 2008, Vol. 36, No. 6demonstrating that ATII employs the AT1 receptor to
eﬀect changes in PDGF-C gene expression (Figure 8).
SMCs are well known for their phenotypically hetero-
geneity, particularly during development and arterial
remodeling in atherosclerosis and restenosis in adults.
Previous studies examining ATII-inducible PDGF-B
expression revealed SMC subtype-speciﬁc responsiveness
(15). ATII regulation of PDGF-A (14) or PDGF-D (16)
expression has only been studied in adult rat SMCs. To
determine whether ATII regulation of PDGF-C expres-
sion is SMC diﬀerentiation state-dependent, we isolated
mRNA from adult rat aortic SMCs exposed to ATII
(10
 7M) for various times and assessed PDGF-C levels
(Figure 9A and B). In contrast to results obtained using
neonatal SMCs (Figures 1A–C, 5B, 6, 7A, B, E and 8),
ATII did not inﬂuence PDGF-C mRNA expression in
adult SMCs (Figure 9A and B), indicating that PDGF-C
expression in SMC is diﬀerentiation state-speciﬁc. We
explored whether the inability of ATII to inﬂuence
PDGF-C expression in adult SMCs is due to the lack
of induction of Egr-1 by ATII in this cell type.
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Figure 9. ATII does not induce PDGF-C expression in rat adult SMCs. mRNA was isolated from adult rat aortic SMCs treated with or without
ATII (10
 7M) for 0.5, 2, 4 or 8h. (A) Real-time PCR and (B) conventional RT-PCR were performed simultaneously for PDGF-C and GAPDH,
a housekeeping gene, as described in the Materials and Methods section. The graph represents PDGF-C expression relative to the expression
of GAPDH to correct for cDNA concentration between samples. The data are representative of three or more independent determinations.
(C) Conventional RT-PCR or (D) real-time PCR was performed simultaneously for Egr-1 as described in the Materials and Methods section.
The graph represents Egr-1 expression relative to the expression of beta-actin to correct for cDNA concentration between samples. The data are
representative of three or more independent determinations. Error bars represent the mean SE. Asterisk (
 ) denotes P<0.05
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Figure 8. ATII-inducible PDGF-C expression acts through the AT1
receptor. WKY12-22 SMCs cells were treated with the AT1R inhibitor
Losartan (1mM) or AT2R inhibitor, PD123319 (1mM) for 1h prior to
stimulation with ATII (10
 7M) for 2h. mRNA was isolated and real-
time PCR was performed simultaneously for PDGF-C and GAPDH, a
housekeeping gene. The graph represents PDGF-C expression relative
to the expression of GAPDH to correct for cDNA concentration
between samples. The data are representative of three or more
independent determinations. Error bars represent the mean SE.
Asterisk (
 ) denotes P<0.05.
Nucleic Acids Research, 2008, Vol. 36, No. 6 1949ATII stimulated Egr-1 mRNA expression in adult SMCs
(Figure 9C and D) as it did together with protein in
neonatal cells (Figure 2B and C). These observations
therefore indicate Egr-1-dependent and -independent
transcriptional control of PDGF-C between these SMC
subtypes. To determine the functional importance of this
upstream element in relation to Egr-1 and Sp1, transient
co-transfection analysis was performed in WKY12-22
SMCs using wild-type (pPDGF-C-797) and mutant
(pPDGF-C-797.mutEgr1) PDGF-C promoter together
with expression vectors for Egr-1 and Sp1. Both tran-
scription factors, as expected, activated the wild-type
PDGF-C promoter (Figure 10A). However, whereas
mutation of the distal element ( 543/ 535) blocked
Egr-1 activation of the PDGF-C promoter (Figure 10A),
disruption of this element did not alter Sp1’s ability to
activate the promoter (Figure 10A). That Egr-1 and Sp1
were overexpressed in this context was demonstrated by
immunoblot analysis (Figure 10B). These ﬁndings demon-
strate that Sp1’s transactivation of the PDGF-C promoter
is not mediated by  543/ 535, although Sp1 binds this
element (Figure 4A–C). SMCs of distinct diﬀerentiation
state respond to changes in the extracellular environment
through diﬀerent pathways (31). The present study
demonstrates that ATII-inducible PDGF-C expression in
SMCs is dissimilarly regulated in cells of neonatal and
adult origin, by providing evidence for a novel ATII-
AT1R-Egr-1-PDGF-C axis in SMCs of neonatal origin,
but not in adult SMCs, where ATII induces Egr-1 but not
PDGF-C. This study also demonstrates that ATII is a
positive regulator of PDGF-C gene expression in neonatal
SMCs, and for the ﬁrst time, deﬁnes ATII as an agonist of
all four known PDGF ligand chains (14–16). Using
nuclear extracts and recombinant proteins, we discovered
this novel upstream element cooperatively binds both
Egr-1 and Sp1, and mediates ATII-inducible PDGF-C
expression. DNAzymes targeting Egr-1 mRNA
established that Egr-1 plays a critical role in ATII-
inducible PDGF-C expression. Additionally, by using
pharmacologic inhibitors of each ATII receptor, AT1R
and AT2R, we demonstrated that ATII acts through
AT1R to induce PDGF-C expression. Element  543/
 535 plays a critical role in both Egr-1- and ATII-
activation of the PDGF-C promoter. Thus, although
Egr-1 is a key regulator of ATII-inducible PDGF-C
expression, this present study invites further investigation
to rationalize diﬀerences in the transcriptional regulation
of PDGF-C between SMC subtypes. This information will
help develop a more detailed understanding of SMC
heterogeneity.
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